132 related articles for article (PubMed ID: 36409433)
1. Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer.
Kamiimabeppu D; Wakatsuki T; Takahari D; Fukuda N; Shimozaki K; Osumi H; Nakayama I; Ogura M; Ooki A; Shinozaki E; Chin K; Yamaguchi K
Int J Clin Oncol; 2023 Jan; 28(1):121-129. PubMed ID: 36409433
[TBL] [Abstract][Full Text] [Related]
2. Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: A case report.
Arakawa Y; Tamura M; Aiba K; Morikawa K; Aizawa D; Ikegami M; Yuda M; Nishikawa K
Oncol Lett; 2017 Sep; 14(3):3039-3042. PubMed ID: 28928842
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Change in Serum Alpha-fetoprotein Level Predicts Treatment Response and Prognosis of Alpha-fetoprotein-producing Gastric Cancer.
Wang R; Li J; Xu D; Li R; Gong P
Medicine (Baltimore); 2020 Nov; 99(47):e23326. PubMed ID: 33217870
[TBL] [Abstract][Full Text] [Related]
4. An analysis of clinical characteristics and prognosis for patients with serum alpha-fetoprotein-positive gastric cancer.
Zuo CT; Ju Q
Minerva Med; 2015 Aug; 106(4):185-91. PubMed ID: 26418320
[TBL] [Abstract][Full Text] [Related]
5. Re-evaluation of the prognosis of alpha-fetoprotein-producing gastric cancer from a single center: a case series study.
Akabane M; Yago A; Haruta S; Ohkura Y; Ueno M; Udagawa H
Langenbecks Arch Surg; 2023 Jan; 408(1):66. PubMed ID: 36695913
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and prognostic characteristics of alpha-fetoprotein-producing gastric cancer.
He R; Yang Q; Dong X; Wang Y; Zhang W; Shen L; Zhang Z
Oncotarget; 2017 Apr; 8(14):23817-23830. PubMed ID: 28423604
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and treatments of patients with alpha-fetoprotein producing gastric carcinoma.
Gong W; Su Y; Liu A; Liu J; Sun D; Jiang T; Xiang J; Chi C; Sun P
Neoplasma; 2018 Mar; 65(3):326-330. PubMed ID: 29788728
[TBL] [Abstract][Full Text] [Related]
8. Hepatoid Adenocarcinoma of Stomach: Emphasis on the Clinical Relationship with Alpha-Fetoprotein-Positive Gastric Cancer.
Chen EB; Wei YC; Liu HN; Tang C; Liu ML; Peng K; Liu T
Biomed Res Int; 2019; 2019():6710428. PubMed ID: 31915699
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological features and prognosis of serum AFP positive gastric cancer: a report of 16 cases.
Liu D; Li B; Yan B; Liu L; Jia Y; Wang Y; Ma X; Yang F
Int J Clin Exp Pathol; 2020; 13(9):2439-2446. PubMed ID: 33042357
[TBL] [Abstract][Full Text] [Related]
10. Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma.
Li W; Li Q; Yu Y; Wang Y; Chen E; Chen L; Wang Z; Cui Y; Liu T
Cancer Manag Res; 2020; 12():11113-11119. PubMed ID: 33173344
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer.
Li N; Bai C; Zhang R; Ma L; Ren X; Zhang J; Fu Z; Zhao L
Transl Oncol; 2021 Feb; 14(2):101004. PubMed ID: 33383486
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
13.
Maruyama S; Furuya S; Shiraishi K; Shimizu H; Akaike H; Hosomura N; Kawaguchi Y; Amemiya H; Kawaida H; Sudo M; Inoue S; Kono H; Ichikawa D
World J Gastrointest Oncol; 2018 Oct; 10(10):344-350. PubMed ID: 30364858
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.
Weng W; Zhang M; Ni S; Tan C; Xu M; Wang X; Sun H; Wang L; Huang D; Sheng W
J Gastrointest Oncol; 2022 Jun; 13(3):1035-1045. PubMed ID: 35837176
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of Hepatic Arterial Infusion Chemotherapy with 5-Fluorouracil/Cisplatin and Systemic Chemotherapy with Ramucirumab in Alpha-Fetoprotein-Producing Gastric Cancer with Multiple Liver Metastases.
Doi Y; Takii Y; Mitsugi K; Kimura K; Mihara Y
Case Rep Oncol Med; 2018; 2018():5402313. PubMed ID: 30534453
[TBL] [Abstract][Full Text] [Related]
16. Characteristic analysis of α-fetoprotein-producing gastric carcinoma in China.
Li XD; Wu CP; Ji M; Wu J; Lu B; Shi HB; Jiang JT
World J Surg Oncol; 2013 Oct; 11():246. PubMed ID: 24083471
[TBL] [Abstract][Full Text] [Related]
17. The Relationship Between D-dimer and Prognosis in the Patients with Serum Alpha-Fetoprotein-Positive Gastric Cancer: A Retrospective Cohort Study.
Zhang X; Wang W; Tian B; Wang Y; Jing J
Clin Med Insights Oncol; 2022; 16():11795549221120158. PubMed ID: 36104997
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
